Allurion Technologies Azioni (NYSE: ALUR)

Ultime notizie per Allurion Technologies (NYSE:ALUR) Azioni

Allurion Technologies

Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Allurion Technologies Inc

Allurion Technologies, Inc. Warrants, each whole warrant exercisable to purchase 1.420455 shares of common stock at an exercise price of $8.10 per share of common stock

Alight (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALIT#NYSE">ALIT</a>) affirms FY2025 Adj EPS guidance from $0.58-$0.64 to $0.58-$0.64 vs $0.60 analyst estimate. Affirms FY2025 sales outlook from $2.32 billion-$2.39 billion to $2.32 billion-$2.39 billion vs $2.35 billion estimate.

News

Guidance

ALIT

Alight Affirms FY2025 Adj EPS Guidance of $0.58-$0.64 vs $0.60 Est; Affirms FY2025 Sales Guidance of $2.32B-$2.39B vs $2.35B Est

Kelly Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KELYB#NASDAQ">KELYB</a>) .

KELYB

Kelly Services expects year-over-year revenue growth of 6.0% to 7.0% in Q2

Acacia Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTG#NASDAQ">ACTG</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $(0.06) by 666.67 percent. This is a 21.43 percent increase over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $124.42 million which beat the analyst consensus estimate of $55.00 million by 126.22 percent. This is a 411.60 percent increase over sales of $24.32 million the same period last year.

Earnings

Earnings Beats

ACTG

Acacia Research Q1 Adj. EPS $0.34 Beats $(0.06) Estimate, Sales $124.42M Beat $55.00M Estimate

Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.88) by 19.32 percent. This is a 29.63 percent decrease over losses of $(0.81) per share from the same period last year.

Earnings Misses

Dyne Therapeutics Q1 EPS $(1.05) Misses $(0.88) Estimate

WIIM

CVNA

Carvana shares are trading higher after the company reported better-than-expected Q1 financial results.

As <a href="https://www.benzinga.com/25/05/45241770/india-fires-missiles-into-pakistani-territory-trump-hopes-fighting-between-nuclear-rivals-ends-very-quickly">India and Pakistan escalate military conflicts</a> this week, the U.S. and China find themselves playing a pivotal role in the arms in South Asia. Records show that India is increasingly purchasing military equipment from the U.S. and other Western suppliers, while Pakistan is turning to China for its defense needs.
What Happened: In April, the U.S. approved a $131 million military sale to India for advanced SeaVision surveillance software, targeted to improve maritime domain awareness in the Indo-Pacific. Since 2008, as per the Library of Congress, the U.S. has sold at least $24 billion worth of arms to India, including heavy transport planes, maritime patrol aircraft, Apache and Chinook helicopters, and Hellfire missiles.
India was once almost completely dependent on Russia for weapons: from 2008–2024, 59% of its arms came from Russia, but that dwindled to 36% in the last five years. The U.S. now makes up 10% of India's total imports, and new deals are extending into joint production: General Electric has proposed co-producing its F414 jet engine in India, and other U.S. firms are deliberating the coproduction of Stryker vehicles and Javelin missiles.
In contrast, Pakistan, once a key recipient of U.S. military aid, now acquires most of its arms from China. According to the Stockholm International Peace Research Institute (SIPRI), about 80% of Pakistan's weapons imports now come from China, including fighter jets, naval frigates, and missile systems.
See Also: <a href="https://www.benzinga.com/25/05/45245186/uk-india-finalize-landmark-free-trade-agreement-amid-tariff-chaos-while-trump-waits-in-the-wings">UK, India Seal $34 Billion Free Trade Deal Amid Tariff Turmoil — As Trump Waits In The Wings</a>
Why It Matters: The change in arms sales echoes wider geopolitical shifts and heightens the risk of direct confrontation in South Asia. As India increases its stock of U.S. military platforms and Pakistan relies on Chinese-made weaponry, future conflicts between these nuclear-armed neighbors may find the U.S. and China's defense systems clashing head-on. The latest developments in South Asia come amid the ongoing trade war between China and the U.S.
On Wednesday, President Donald Trump said that he had <a href="https://www.benzinga.com/25/05/45273459/no-trump-shuts-down-tariff-rollback-buzz-ahead-of-china-talks">no intention of easing the 145% tariffs on Chinese goods</a>. This comes just before U.S. Treasury Secretary Scott Bessent and Trade Representative Jamieson Greer are scheduled to meet China&#8217;s Vice-Premier He Lifeng from May 9 to 12 in Geneva.
Prior to the meeting, Beijing has warned against any attempt to use dialogue as a tool of <a href="https://www.benzinga.com/25/05/45246445/china-warns-us-not-to-use-coercion-and-extortion-tactics-ahead-of-first-major-trade-talks-in-geneva-says-it-will-never-accept-it-if-americans-use-dialogue-as-smokescreen">&#8220;coercion and extortion",</a> vowing that it will "never accept" terms unilaterally imposed by the U.S.
Read Next: <a href="https://www.benzinga.com/markets/25/05/45279335/economist-brad-setser-sounds-alarm-on-chinas-hidden-trade-surplus-suggests-billions-in-capital-outflows-are-being-masked">Economist Brad Setser Sounds Alarm On China&#8217;s Hidden Trade Surplus, Suggests Billions In Capital Outflows Are Being Masked</a>
Image Via Shutterstock

Politics

Global

General

US And China Accelerate Arms Race With Billions In Military Sales To Nuclear Neighbors, As India Turns To Washington And Pakistan Deepens Ties With Beijing Amid Escalating Border Conflict

DCTH

Delcath Systems Q1 EPS $0.03 Beats $0.01 Estimate, Sales $19.80M Beat $16.83M Estimate

ULL-YEAR AND SECOND QUARTER 2025 OUTLOOK:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="3">Full-Year 2025 Key Guidance Metrics</td>
</tr>
<tr>
<td>2024/2025 Two-Year Adjusted FCF</td>
<td>$900 million – 1.1 billion</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Corporate Expenses</td>
<td>$40 – 45 million</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Depreciation</td>
<td>$60 – 65 million</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Amortization</td>
<td>$33 – 37 million</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Interest Expense</td>
<td>$165 – 170 million</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="2">Capital Expenditures</td>
<td>$50 – 60 million</td>
</tr>
<tr>
<td>Effective Tax Rate</td>
<td>22.0 – 23.0%</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="3">Second Quarter 2025 Key Guidance Metrics</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="3">Reflects expectations relative to second quarter 2024 results</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="2">Total Company GAAP Revenue</td>
<td colspan="2">Down -4% to -7%</td>
</tr>
<tr>
<td colspan="2">Total Non-GAAP Operating Expenses</td>
<td colspan="2">Flat to down -2%</td>
</tr>
</tbody>
</table>
</figure>

TGNA

Tegna Sees Q2 Sales $660.640M-$681.948M vs $678.28M Est

Inspired Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSE#NASDAQ">INSE</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.01 by 1200 percent. This is a 750 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $60.40 million which missed the analyst consensus estimate of $67.34 million by 10.31 percent. This is a 4.28 percent decrease over sales of $63.10 million the same period last year.

INSE

Inspired Entertainment Q1 Adj. EPS $0.13 Beats $0.01 Estimate, Sales $60.40M Miss $67.34M Estimate

Knight Therapeutics (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GUD#TSX">GUD</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.01) by 300 percent. This is a 150 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $88.08 million which beat the analyst consensus estimate of $86.45 million by 1.89 percent. This is a 1.70 percent increase over sales of $86.60 million the same period last year.

TSX:GUD

Knight Therapeutics Q1 EPS $0.02 Beats $(0.01) Estimate, Sales $88.08M Beat $86.45M Estimate

<a href="https://www.globenewswire.com/Tracker?data=ByQ0hAqMA-BFwHQ_c9wwUwivhSBvctYECkfqucmDzRi624_OCF6QcetLLhtOMTxF7nVplwYavWeiHwvNFfQhdA==">Altimmune, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced the presentation of new analyses at the European Association for the Study of the Liver (EASL) Congress&#x2122; in&nbsp;Amsterdam, The Netherlands. The presentation focuses on the use of the MASH Resolution Index (MASHResInd) algorithm to predict MASH resolution on biopsy in patients treated with pemvidutide, Altimmune's 1:1 GLP-1/glucagon dual receptor agonist.

Altimmune Announces Presentation Of New Analyses Predicting High Rates of MASH Resolution On Biopsy Following Pemvidutide Treatment At EASL International Liver Congress

Griffon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFF#NYSE">GFF</a>) affirms FY2025 sales outlook from $2.60 billion to $2.60 billion vs $2.60 billion estimate.

Griffon Affirms FY2025 Sales Guidance of $2.60B vs $2.60B Est

2025 FULL YEAR FINANCIAL GUIDANCE
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(in billions)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">2025</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Consolidated Adjusted EBITDA2</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$6.5</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$7.0</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Distributable Cash Flow2</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$4.1</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$4.6</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Cheniere Energy Reaffirms 2025 Guidance Of Adjusted EBITDA $6.5B–$7B And Distributable Cash Flow Of $4.1B–$4.6B

Knight Therapeutics (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GUD#TSX">GUD</a>) affirms FY2025 sales outlook from $390.00 million-$405.00 million to $390.00 million-$405.00 million vs $397.74 million estimate.

Knight Therapeutics Affirms FY2025 Sales Guidance of $390.00M-$405.00M vs $397.74M Est

NetScout Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCT#NASDAQ">NTCT</a>) is looking for FY2026 Adj EPS of $2.25-$2.40 vs $2.27 analyst estimate. sees sales of $825.000 million-$865.000 million vs $831.56 million analyst estimate.

NTCT

NetScout Systems Sees FY2026 Adj EPS $2.25-$2.40 vs $2.27 Est; Sees Sales $825.000M-$865.000M vs $831.56M Est

NetScout Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCT#NASDAQ">NTCT</a>) is looking for FY2026 GAAP EPS of $1.07-$1.22 vs $0.95 analyst estimate..

NetScout Systems Sees FY2026 GAAP EPS $1.07-$1.22 vs $0.95 Est

CARS

Cars.com Suspends FY25 Revenue Guidance Due To Tariff Impacts

Talen Energy shares are trading lower after the company reported worse-than-expected Q1 EPS results.

Cronos Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CRON#TSX">CRON</a>) reported quarterly earnings of $0.02 per share. This is a 300 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $32.26 million which missed the analyst consensus estimate of $45.44 million by 29.00 percent. This is a 27.58 percent increase over sales of $25.29 million the same period last year.

Comments

Allurion Technologies

Notizie

Ultime notizie per Allurion Technologies (NYSE:ALUR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO